Amarin Corp Plc (AMRN)

[alm2]

Marjac /Study- I have listened also - the oral hearing oddly did not seem to have the period focus as the announced in the decision as to the rehearing - the re hearing announcement focus seemed to be the extent of damages requiring reduction because infringement might not have applied across the whole period of time
The oral hearing did not appear to have this focus but rather on whether the jury had before it evidence which supported infringement -a point returned to repeatedly by Judge Moore and GSK counsel in the affirmative
Thus I find myself somewhat confused as to the rehearing purpose
Takeaway was that GSK case appeared as strong as ever and hard to see how the outcome will alter - perhaps Newman wants to further counter Prosts dissent -as evidenced by her intervention as to protection for old drug innovation studies - they won’t happen unless patent protected and it is vital to the nations health that such innovations are rewarded -not prostituted by generics
Amarins action against Hikma and health net is multi purpose - get this into a jury trial and The defendants are in a lottery ...they could easily loose big time and treble damages apply -delay of years is achieved without other generics entering and insurers fearing they will be litigated against

There is much here to encourage long shareholders in Amarin and Marjac et al are about to open a huge can of worms in Rule 60
The Amarin Wars continue and are opening up on different fronts -
Alm